Volume 27, Issue 6 e12937
ORIGINAL ARTICLE

Quality of online information about phase I clinical cancer trials in Sweden, Denmark and Norway

Tove E. Godskesen

Corresponding Author

Tove E. Godskesen

Department of Health Care Sciences, Ersta Sköndal Bräcke University College, Stockholm, Sweden

Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden

Correspondence

Tove E. Godskesen, Department of Health Care Sciences, Ersta Sköndal Bräcke University College, Stockholm, Sweden.

Emails: [email protected], [email protected]

Search for more papers by this author
Josepine Fernow

Josepine Fernow

Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden

Search for more papers by this author
Stefan Eriksson

Stefan Eriksson

Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden

Search for more papers by this author
First published: 02 October 2018
Citations: 3

Abstract

Patients increasingly search for online information about clinical trials. Little is known about the quality and readability of the information in these databases. Therefore, the aim of this study was to assess the quality and readability of online information available to the public on phase I clinical cancer trials in Sweden, Denmark and Norway. A qualitative content analysis was made of 19 online trial descriptions from three public websites in Sweden, Denmark and Norway, and the readability of the documents was tested. Both the quality of the content and the readability scores were best for the Danish information. The Swedish texts were very short and were the least readable. Overall, the quality of the information was highly variable and nearly all the documents were misleading in part. Furthermore, the descriptions provided almost no information about possible adverse effects or disadvantages of study participation. This study highlights a communication problem and proposes new ways of presenting studies that are less suggestive of positive outcomes, arguing that we should be more careful to include information about adverse effects, and that the use of simple measures like readability testing can be useful as an indicator of text quality.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.